Literature DB >> 28492885

Treatment of KRAS-Mutant Non-Small Cell Lung Cancer: The End of the Beginning for Targeted Therapies.

Jacob Kaufman1, Thomas E Stinchcombe2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28492885     DOI： 10.1001/jama.2017.3436

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  Treatment of lung adenocarcinoma brain metastases: what is the role of radiotherapy in the age of precision medicine?

Authors:  Elizabeth J Buss; Tony J C Wang
Journal:  Transl Lung Cancer Res       Date:  2018-12

2.  PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.

Authors:  Malabika Sen; Audrey Kindsfather; Ludmila Danilova; Feng Zhang; Raffaele Colombo; Matthew G LaPorte; Brenda F Kurland; Donna M Huryn; Peter Wipf; James G Herman
Journal:  Epigenetics       Date:  2019-10-13       Impact factor: 4.528

3.  Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients.

Authors:  Si-Yang Liu; Hao Sun; Jia-Ying Zhou; Guang-Ling Jie; Zhi Xie; Yang Shao; Xian Zhang; Jun-Yi Ye; Chun-Xiang Chen; Xu-Chao Zhang; Qing Zhou; Jin-Ji Yang; Yi-Long Wu
Journal:  Biomark Res       Date:  2020-06-25

Review 4.  MEK inhibitors for the treatment of non-small cell lung cancer.

Authors:  Jing Han; Yang Liu; Sen Yang; Xuan Wu; Hongle Li; Qiming Wang
Journal:  J Hematol Oncol       Date:  2021-01-05       Impact factor: 17.388

Review 5.  PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?

Authors:  Asad Ullah; Steven Pulliam; Nabin Raj Karki; Jaffar Khan; Sana Jogezai; Sandresh Sultan; Lal Muhammad; Marjan Khan; Nimra Jamil; Abdul Waheed; Sami Belakhlef; Intisar Ghleilib; Eric Vail; Saleh Heneidi; Nagla Abdel Karim
Journal:  Clin Pract       Date:  2022-08-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.